SPRY vs. DAWN

Last updated Apr 1, 2026

Compare and contrast key facts about Silverback Therapeutics Inc (SPRY) and Day One Biopharmaceuticals, Inc. (DAWN).

Performance

SPRY vs. DAWN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Silverback Therapeutics Inc (SPRY) and Day One Biopharmaceuticals, Inc. (DAWN). The values are adjusted to include any dividend payments, if applicable.

SPRY vs. DAWN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SPRY Silverback Therapeutics Inc	-31.07%	10.43%	92.52%	-35.76%	28.08%	-75.20%
DAWN Day One Biopharmaceuticals, Inc.	130.04%	-26.44%	-13.22%	-32.16%	27.72%	-34.92%

Fundamentals

EPS SPRY : -$1.74 DAWN : -$1.47
PS Ratio SPRY : 9.39 DAWN : 16.56
Total Revenue (TTM) SPRY : $84.28M DAWN : $133.67M
Gross Profit (TTM) SPRY : $45.85M DAWN : $119.56M
EBITDA (TTM) SPRY : -$175.98M DAWN : -$141.73M

Returns By Period

In the year-to-date period, SPRY achieves a -31.07% return, which is significantly lower than DAWN's 130.04% return.

SPRY

• 1D: 2.75%
• 1M: -13.47%
• YTD: -31.07%
• 6M: -20.10%
• 1Y: -36.17%
• 3Y*: 7.25%
• 5Y*: -28.93%
• 10Y*: —

DAWN

• 1D: 0.09%
• 1M: 102.26%
• YTD: 130.04%
• 6M: 204.11%
• 1Y: 170.37%
• 3Y*: 17.05%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SPRY vs. DAWN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRY

SPRY Risk / Return Rank: 21
SPRY Sharpe Ratio Rank: 17
SPRY Sortino Ratio Rank: 19
SPRY Omega Ratio Rank: 20
SPRY Calmar Ratio Rank: 23
SPRY Martin Ratio Rank: 24

DAWN

DAWN Risk / Return Rank: 92
DAWN Sharpe Ratio Rank: 87
DAWN Sortino Ratio Rank: 94
DAWN Omega Ratio Rank: 91
DAWN Calmar Ratio Rank: 95
DAWN Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRY vs. DAWN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Silverback Therapeutics Inc (SPRY) and Day One Biopharmaceuticals, Inc. (DAWN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SPRY	DAWN	Difference
Sharpe ratio Return per unit of total volatility	-0.54	1.68	-2.22
Sortino ratio Return per unit of downside risk	-0.50	3.42	-3.92
Omega ratio Gain probability vs. loss probability	0.94	1.42	-0.48
Calmar ratio Return relative to maximum drawdown	-0.56	6.08	-6.65
Martin ratio Return relative to average drawdown	-0.97	12.95	-13.93
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SPRY vs. DAWN - Sharpe Ratio Comparison

The current SPRY Sharpe Ratio is -0.54, which is lower than the DAWN Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of SPRY and DAWN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SPRY	DAWN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.54	1.68	-2.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.24	-0.04	-0.20

Correlation

The correlation between SPRY and DAWN is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SPRY vs. DAWN - Dividend Comparison

Neither SPRY nor DAWN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SPRY vs. DAWN - Drawdown Comparison

The maximum SPRY drawdown since its inception was -95.20%, which is greater than DAWN's maximum drawdown of -79.51%. Use the drawdown chart below to compare losses from any high point for SPRY and DAWN.

Drawdown Indicators

	SPRY	DAWN	Difference
Max Drawdown Largest peak-to-trough decline	-95.20%	-79.51%	-15.69%
Max Drawdown (1Y) Largest decline over 1 year	-63.32%	-27.23%	-36.09%
Max Drawdown (5Y) Largest decline over 5 years	-93.45%	—	—
Current Drawdown Current decline from peak	-86.71%	-23.21%	-63.50%
Average Drawdown Average peak-to-trough decline	-77.98%	-47.87%	-30.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	36.73%	12.79%	+23.94%

Volatility

SPRY vs. DAWN - Volatility Comparison

The current volatility for Silverback Therapeutics Inc (SPRY) is 17.65%, while Day One Biopharmaceuticals, Inc. (DAWN) has a volatility of 55.60%. This indicates that SPRY experiences smaller price fluctuations and is considered to be less risky than DAWN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SPRY	DAWN	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.65%	55.60%	-37.95%
Volatility (6M) Calculated over the trailing 6-month period	51.95%	80.38%	-28.43%
Volatility (1Y) Calculated over the trailing 1-year period	67.04%	101.86%	-34.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.53%	93.26%	-12.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	81.43%	93.26%	-11.83%

Financials